Latest news and press releases about Ligand Pharmaceuticals Incorporated (LGND): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions.
Price
| Price | $284.47 |
| Market Cap | $5.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 27.49 |
| Price / Book | 5.71 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 98.58% |
| Operating Margin | 34.74% |
| Net Margin | 67.88% |
Related companies: ACAD · ADMA · BLTE · CRNX · DYN · MIRM · NAMS
Explore sector: Healthcare · Biotechnology
More sections of LGND: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks